MorphoSys AG: MorphoSys Reports Preliminary 2021 Monjuvi U.S

Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million)Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 millionPLANEGG / MUNICH, GERMANY / ACCESSWIRE

Related Keywords

Germany , Boston , Massachusetts , United States , Planegg , Bayern , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Myles Clouston , Jeanette Bressi , Linkedin , Xencor Inc , Twitter , Drug Administration , Nasdaq , Us Communications , Exchange Commission , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys , Reports , Reliminary , 021 , Monjuvi , Sales , Rovides , 022 , Financial , Guidance ,